Resonance expands into liver fibrosis
04 November, 2005 by Helen SchullerPerth-based Resonance Health Group (ASX:RHT) will progress to being a "two-product company" with the commercialisation of a new test for liver fibrosis, the company's managing director said this week.
Probiomics launches share purchase plan
04 November, 2005 by Ruth BeranProbiomics (ASX:PCC), formerly VRI BioMedical, has launched a share purchase plan (SPP) which could raise AUD$2 million if fully subscribed.
WEHI to double in size under expansion plans
04 November, 2005 by Graeme O'NeillThe Victorian government has presented a birthday gift for Melbourne's Walter and Eliza Hall Institute for Medical Research: a AUD$50 million contribution towards the cost of a new seven-storey wing that will double the institute's size.
NZ company BrainZ to list on ASX in December
02 November, 2005 by Helen SchullerNew Zealand medical device company BrainZ Instruments, which develops monitors for the detection of brain injury, has lodged a prospectus for an IPO to raise up to AUD$13 million on the ASX.
Life Therapeutics signs US bioterror contract
01 November, 2005 by Helen SchullerSydney-based Life Therapeutics (ASX:LFE) has been awarded a contract worth US$4.7 million (AUD$6.29 million) to supply specialty plasma for the treatment and prevention of smallpox in the general population, and to counter bioterrorism.
Domantis lung study nets 'exciting' results
27 October, 2005 by Graeme O'NeillUK human domain-antibody (dAb) developer Domantis has reported spectacular success in trial of an inhaled anti-inflammatory dAB in an in vivo model of chronic obstructive pulmonary disorder (COPD).
Phylogica and Sunshine Heart net grants
26 October, 2005 by Helen SchullerDrug developer Phylogica (ASX:PYC) and artificial heart company Sunshine Heart (ASX:SHC) have been awarded a Commercial Ready grants from AusIndustry, worth $2.27 million and $2.223 million respectively.
Monash team determines cancer protein form
25 October, 2005 by Graeme O'NeillMonash University researchers have determined the structure of a key oncoprotein, JAK2, being targeted by Melbourne oncology drug developer Cytopia (ASX:CYT).
Phospha E linked to healthy cardiovascular function
21 October, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has found its vitamin product Phospha E has reduced LDL-C (bad cholesterol) concentrations in blood by up to 44 per cent in an animal study.
Apollo starts psoriasis trial
20 October, 2005 by Helen SchullerSydney-based biopharma Apollo Life Sciences (ASX:AOP) has commenced its phase Ib clinical trial for a topical psoriasis treatment, developed from human-expressed protein.
Panvax signs agreement with US institute to develop malaria vaccine
18 October, 2005 by Graeme O'NeillMelbourne's Austin Research Institute (ARI) and vaccine developer Panvax have signed an agreement with the Walter Reed Army Institute of Research to develop an experimental malaria vaccine.
Plantigens: best prospect for defeating Malaria?
17 October, 2005 by Graeme O'NeillAustralian malaria vaccine researcher Professor Ross Coppell says smallpox was eradicated from the planet because the mass vaccination campaign employed a powdered formulation of dried, attenuated virus.
Norwood to commence phase II cancer vaccine trial
13 October, 2005 by Helen SchullerMelbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed an agreement for a phase II collaboration with the University of Texas MD Anderson Cancer Centre of Houston to determine whether its investigational melanoma cancer vaccine generates an enhanced immune response.
Prozac prevents onset of Huntington's disease in mice
13 October, 2005 by Graeme O'NeillA collaborative study by Australian and UK neuroscientists has shown that the anti-depressant fluoxetine (Prozac) prevents the onset of Huntington's disease (HD) in transgenic HD mice.
Avantogen cancer gene test partnership progressing
10 October, 2005 by Ruth BeranA partnership initiated in 2003 between Avantogen (ASX:ACU) (formerly Australian Cancer Technology) and Prof Ursula Kees at Perth's Telethon Institute for Child Health Research is closer to developing a diagnostic test to enable more effective treatment of cancer.
